For the year ending 2025-12-31, RVMDW had -$158,159K decrease in cash & cash equivalents over the period. -$913,731K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -1,131,301 |
| Loss on disposal of fixed assets | -32 |
| Amortization of intangible assets | 870 |
| Stock-based compensation expense | 118,389 |
| Depreciation and amortization | 7,780 |
| Change in fair value of warrant liability and contingent earn-out shares | 15,358 |
| Non-cash interest expense on liabilities related to sale of future royalties | 24,231 |
| Net amortization of premium or discount on marketable securities | 27,831 |
| Amortization of operating lease right-of-use asset | 7,908 |
| Accounts receivable | 0 |
| Prepaid expenses and other current assets | 9,667 |
| Accounts payable | 9,535 |
| Accrued expenses and other current liabilities | 112,267 |
| Deferred revenue | 0 |
| Operating lease liability | -957 |
| Deferred tax liability | 0 |
| Long-term deposits | 12,020 |
| Other noncurrent assets | 12,872 |
| Other noncurrent liabilities | 537 |
| Net cash used in operating activities | -897,741 |
| Purchases of marketable securities | 1,794,850 |
| Maturities of marketable securities | 1,922,514 |
| Sales of marketable securities | 6,384 |
| Purchases of property and equipment | 15,990 |
| Net cash provided by (used in) investing activities | 118,058 |
| Cash, cash equivalents and restricted cash acquired in connection with eqrx acquisition, net of transaction costs | 0 |
| Proceeds from the sale of future royalties, net of issuance costs | 244,215 |
| Proceeds from issuance of common stock, net of issuance costs | 0 |
| Proceeds from issuance of pre-funded warrants, net of transaction costs | 0 |
| Proceeds from issuance of common stock from at-the-market offering, net of transaction costs | 347,915 |
| Proceeds from issuance of common stock pursuant to stock option exercises | 21,134 |
| Proceeds from issuance of common stock related to employee stock purchase plan | 8,036 |
| Tax payment for common stock withheld in satisfaction of withholding tax requirements | 0 |
| Exercise of warrants | 4 |
| Payments of deferred offering costs | -220 |
| Net cash provided by financing activities | 621,524 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -158,159 |
| Cash, cash equivalents and restricted cash - beginning of year | 546,762 |
| Cash, cash equivalents and restricted cash - end of year | 388,603 |
Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)